End­points hon­ors 20 women su­per­charg­ing drug R&D; Omi­cron is a 'stress test' for the next pan­dem­ic; Roche and Genen­tech strike an AI pact with Re­cur­sion; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

The bulk of this week’s re­port is brought to you by End­points ed­i­tors Nicole De­Feud­is and Max Gel­man, who are cov­er­ing for me as I take a few days off af­ter the big Women in Bio­phar­ma R&D event. We are re­al­ly proud of both the spe­cial re­port and the live pan­el, which fea­tured some great sto­ries from trail­blaz­ing lead­ers and in­sights on gen­der di­ver­si­ty in biotech. Do check them out be­low if you haven’t had a chance.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER